Thelansis’s “Clostridium Difficile Infection (CDI) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Clostridioides difficile (formerly Clostridium difficile) is a Gram-positive, anaerobic, spore-forming bacillus that opportunistically colonizes the human gastrointestinal tract following the profound disruption of the normal colonic microbiota, most classically secondary to broad-spectrum antibiotic exposure. Pathogenesis is driven by the fecal-oral transmission of highly resilient spores and the subsequent elaboration of two potent exotoxins, Toxin A (enterotoxin) and Toxin B (cytotoxin)—and occasionally a binary toxin in hypervirulent strains like NAP1/BI/027—which induce severe cytoskeletal disruption, mucosal inflammation, and cellular necrosis. Clinically, C. difficile infection (CDI) ranges from self-limiting secretory diarrhea to life-threatening pseudomembranous colitis, toxic megacolon, bowel perforation, and septic shock, solidifying its status as the leading cause of healthcare-associated infective diarrhea worldwide. Because the spores are intrinsically resistant to standard antimicrobial eradication, the clinical hallmark of CDI is a notoriously high rate of disease recurrence. Consequently, the modern therapeutic paradigm has shifted dramatically; while targeted antibiotics like fidaxomicin or oral vancomycin remain the frontline standard of care for acute infection, the prevention of recurrence now heavily leverages monoclonal antibodies (such as bezlotoxumab) against Toxin B and transformative microbiome restoration therapies—including fecal microbiota transplantation (FMT) and novel, synthetic live biotherapeutic products—to reestablish colonic colonization resistance durably.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Clostridium Difficile Infection (CDI) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report
Our team will get in touch with you shortly about the Clostridium Difficile Infection (CDI) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report.